Media Press Kit

hVIVO is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.

Explore valuable resources below, featuring the most recent hVIVO plc investor presentation, officially approved company descriptions, and captivating images suitable for editorial use, provided the association with hVIVO, Venn Life Sciences, hLAB and FluCamp is prominently identifiable. Please note that commercial usage is strictly prohibited. 

Open Orphan logo on March 2022 presentation

Download Latest Presentation

10 Sep 2024
H1 24 Results
Download

Images - hVIVO

Download icon
Cathal Friel – Chairman hVIVO plc
(152 KB - JPG)
Download icon
Dr. Yamin ‘Mo’ Khan – Chief Executive Officer hVIVO plc
(177 KB - JPG)
Download icon
Stephen Pinkerton – Chief Financial Officer hVIVO plc
(640 KB - JPG)
Download icon
Dr Andrew Catchpole – Chief Scientific Officer hVIVO plc
(196 KB - JPG)
Download icon
Adam French – VP of Clinical Operations
(135 KB - JPG)
Download icon
Dr Mariya Kalinova – Medical Director
(94 KB - JPG)
Download icon
hVIVO Inoculation 1
(543 KB - JPG)
Download icon
hVIVO Inoculation 2
(555 KB - JPG)
Download icon
hVIVO Inoculation 3
(461 KB - JPG)
Download icon
hVIVO Inoculation 4
(338 KB - JPG)
Download icon
Canary Wharf Quarantine Room 1
(2 MB - PNG)
Download icon
hLAB 1
(308 KB - JPG)
Download icon
hLAB 2
(297 KB - JPG)
Download icon
hLAB 3
(755 KB - JPG)
Download icon
hLAB 4
(793 KB - JPG)
Download icon
Canary Wharf Meeting Room
(570 KB - JPG)
Download icon
FluCamp 1
(2 MB - PNG)
Download icon
FluCamp 2
(1.7 MB - PNG)
Download icon
FluCamp 3
(1.6 MB - PNG)
Download icon
Dr. Yamin ‘Mo’ Khan – At hVIVO's Office in Canary Wharf
(709 KB - JPG)

hVIVO Description

hVIVO plc (AIM: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit participants / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp participant screening facilities in London and Manchester.

If you’re a potential customer, job seeker, health professional or an investor, find out how we can help you.

Contact hVIVO
chevron-downarrow-up